A systems biology approach to dynamic modeling and inter-subject variability of statin pharmacokinetics in human hepatocytes

BackgroundThe individual character of pharmacokinetics is of great importance in the risk assessment of new drug leads in pharmacological research. Amongst others, it is severely influenced by the properties and inter-individual variability of the enzymes and transporters of the drug detoxification system of the liver. Predicting individual drug biotransformation capacity requires quantitative and detailed models.ResultsIn this contribution we present the de novo deterministic modeling of atorvastatin biotransformation based on comprehensive published knowledge on involved metabolic and transport pathways as well as physicochemical properties. The model was evaluated on primary human hepatocytes and parameter identifiability analysis was performed under multiple experimental constraints. Dynamic simulations of atorvastatin biotransformation considering the inter-individual variability of the two major involved enzymes CYP3A4 and UGT1A3 based on quantitative protein expression data in a large human liver bank (n = 150) highlighted the variability in the individual biotransformation profiles and therefore also points to the individuality of pharmacokinetics.ConclusionsA dynamic model for the biotransformation of atorvastatin has been developed using quantitative metabolite measurements in primary human hepatocytes. The model comprises kinetics for transport processes and metabolic enzymes as well as population liver expression data allowing us to assess the impact of inter-individual variability of concentrations of key proteins. Application of computational tools for parameter sensitivity analysis enabled us to considerably improve the validity of the model and to create a consistent framework for precise computer-aided simulations in toxicology.

[1]  U. Christians,et al.  Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar? , 1998, Pharmacology & therapeutics.

[2]  Tatiana Nikolskaya,et al.  Modeling of human cytochrome p450-mediated drug metabolism using unsupervised machine learning approach. , 2003, Journal of medicinal chemistry.

[3]  M. Nishimura,et al.  Tissue-specific mRNA expression profiles of human ATP-binding cassette and solute carrier transporter superfamilies. , 2005, Drug metabolism and pharmacokinetics.

[4]  Matteo Santin,et al.  Strategies in Regenerative Medicine , 2009 .

[5]  Peter-Tobias Stoll,et al.  Charitable State-Controlled Foundation Human Tissue and Cell Research: Ethic and Legal Aspects in the Supply of Surgically Removed Human Tissue For Research in the Academic and Commercial Sector in Germany , 2004, Cell and Tissue Banking.

[6]  M. M. Bradford.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[7]  Hassane Izzedine,et al.  Statins' dosage in patients with renal failure and cyclosporine drug-drug interactions in transplant recipient patients. , 2005, International journal of cardiology.

[8]  Olga Khersonsky,et al.  Structure-reactivity studies of serum paraoxonase PON1 suggest that its native activity is lactonase. , 2005, Biochemistry.

[9]  Robert Barouki,et al.  Opposite regulation of the human paraoxonase-1 gene PON-1 by fenofibrate and statins. , 2003, Molecular pharmacology.

[10]  Johann Gasteiger,et al.  Ligand-Based Models for the Isoform Specificity of Cytochrome P450 3A4, 2D6, and 2C9 Substrates , 2007, J. Chem. Inf. Model..

[11]  J. Houston,et al.  Uptake and Intracellular Binding of Lipophilic Amine Drugs by Isolated Rat Hepatocytes and Implications for Prediction of in Vivo Metabolic Clearance , 2006, Drug Metabolism and Disposition.

[12]  Tingjun Hou,et al.  ADME Evaluation in Drug Discovery, 8. The Prediction of Human Intestinal Absorption by a Support Vector Machine , 2007, J. Chem. Inf. Model..

[13]  Manfred Kansy,et al.  Design, Data Analysis, and Simulation of in Vitro Drug Transport Kinetic Experiments Using a Mechanistic in Vitro Model , 2008, Drug Metabolism and Disposition.

[14]  Jochen Schmid,et al.  Continuously microscopically observed and process-controlled cell culture within the SlideReactor: proof of a new concept for cell characterization. , 2007, Tissue engineering.

[15]  Ivan Nestorov,et al.  Whole-body physiologically based pharmacokinetic models , 2007, Expert opinion on drug metabolism & toxicology.

[16]  Walter Schmitt,et al.  PK-Sim®: a physiologically based pharmacokinetic ‘whole-body’ model , 2003 .

[17]  Jan G. Hengstler,et al.  The Holy Grail of Hepatocyte Culturing and Therapeutic Use , 2009 .

[18]  Thomayant Prueksaritanont,et al.  β-Oxidation of Simvastatin in Mouse Liver Preparations , 2001 .

[19]  R K Jain,et al.  Physiologically based pharmacokinetic modeling: principles and applications. , 1983, Journal of pharmaceutical sciences.

[20]  R. Sunahara,et al.  Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificitiess⃞s⃞ The online version of this article (available at http://www.jlr.org) contains additional text, figures, and references. Published, JLR Papers in Press, March 16, 2005. DOI 10.1194/jlr.M , 2005, Journal of Lipid Research.

[21]  L. Benet,et al.  Effect of OATP1B Transporter Inhibition on the Pharmacokinetics of Atorvastatin in Healthy Volunteers , 2007, Clinical pharmacology and therapeutics.

[22]  Hugh A Barton,et al.  Approaches for Applications of Physiologically Based Pharmacokinetic Models in Risk Assessment , 2008, Journal of toxicology and environmental health. Part B, Critical reviews.

[23]  Tatiana Nikolskaya,et al.  Early prediction of drug metabolism and toxicity: systems biology approach and modeling. , 2004, Drug discovery today.

[24]  J. Turgeon,et al.  Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. , 1998, Trends in pharmacological sciences.

[25]  P. Jeffrey,et al.  Utility of metabolic stability screening: comparison of in vitro and in vivo clearance , 2001, Xenobiotica; the fate of foreign compounds in biological systems.

[26]  George Loizou,et al.  Physiologically based pharmacokinetic modelling , 2003 .

[27]  Sean Ekins,et al.  A Ligand-Based Approach to Understanding Selectivity of Nuclear Hormone Receptors PXR, CAR, FXR, LXRα, and LXRβ , 2002, Pharmaceutical Research.

[28]  Sonu Sundd Singh,et al.  Preclinical pharmacokinetics: an approach towards safer and efficacious drugs. , 2006, Current drug metabolism.

[29]  Robert J Riley,et al.  THE BINDING OF DRUGS TO HEPATOCYTES AND ITS RELATIONSHIP TO PHYSICOCHEMICAL PROPERTIES , 2005, Drug Metabolism and Disposition.

[30]  P. Toutain,et al.  Free drug fraction vs free drug concentration: a matter of frequent confusion. , 2002, Journal of veterinary pharmacology and therapeutics.

[31]  Angela Spivey,et al.  Systems Biology: The Big Picture , 2004, Environmental health perspectives.

[32]  L. Rashed,et al.  Comparative study between the effect of the peroxisome proliferator activated receptor‐α ligands fenofibrate and n‐3 polyunsaturated fatty acids on activation of 5′‐AMP‐activated protein kinase‐α1 in high‐fat fed rats , 2009, The Journal of pharmacy and pharmacology.

[33]  J. Lin,et al.  Sense and nonsense in the prediction of drug-drug interactions. , 2000, Current drug metabolism.

[34]  Kim L. R. Brouwer,et al.  The Complexities of Hepatic Drug Transport: Current Knowledge and Emerging Concepts , 2004, Pharmaceutical Research.

[35]  H. Kitano.  Systems Biology: A Brief Overview , 2002, Science.

[36]  Peter J H Webborn,et al.  Prediction of the Pharmacokinetics of Atorvastatin, Cerivastatin, and Indomethacin Using Kinetic Models Applied to Isolated Rat Hepatocytes , 2008, Drug Metabolism and Disposition.

[37]  Michael Böhm,et al.  Organic anion transporting polypeptide 2B1 is a high‐affinity transporter for atorvastatin and is expressed in the human heart , 2006, Clinical pharmacology and therapeutics.

[38]  Sean Ekins,et al.  A pharmacophore for human pregnane X receptor ligands. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[39]  Jing-Tao Wu,et al.  Strategy of utilizing in vitro and in vivo ADME tools for lead optimization and drug candidate selection. , 2005, Current topics in medicinal chemistry.

[40]  Chongwoo Yu,et al.  Atorvastatin Glucuronidation Is Minimally and Nonselectively Inhibited by the Fibrates Gemfibrozil, Fenofibrate, and Fenofibric Acid , 2007, Drug Metabolism and Disposition.

[41]  Albert S. Kearney,et al.  The Interconversion Kinetics, Equilibrium, and Solubilities of the Lactone and Hydroxyacid Forms of the HMG-CoA Reductase Inhibitor, CI-981 , 1993, Pharmaceutical Research.

[42]  J. Timmer,et al.  Data-Based Mathematical Modeling of Vectorial Transport across Double-Transfected Polarized Cells , 2007, Drug Metabolism And Disposition.

[43]  Tommy B Andersson,et al.  An evaluation of the in vitro metabolism data for predicting the clearance and drug-drug interaction potential of CYP2C9 substrates. , 2004, Drug Metabolism And Disposition.

[44]  Katrin Marcus,et al.  Mass spectrometry‐based absolute quantification of microsomal cytochrome P450 2D6 in human liver , 2009, Proteomics.

[45]  T. Sakaeda,et al.  Effects of Acid and Lactone Forms of Eight HMG-CoA Reductase Inhibitors on CYP-Mediated Metabolism and MDR1-Mediated Transport , 2005, Pharmaceutical Research.

[46]  Michael Aviram,et al.  Paraoxonases (PON1, PON2, PON3) analyses in vitro and in vivo in relation to cardiovascular diseases. , 2008, Methods in molecular biology.

[47]  B. H. Stewart,et al.  Atorvastatin Coadministration May Increase Digoxin Concentrations by Inhibition of Intestinal P‐Glycoprotein‐Mediated Secretion , 2000, Journal of clinical pharmacology.

[48]  David B Duignan,et al.  High throughput ADME screening: practical considerations, impact on the portfolio and enabler of in silico ADME models. , 2008, Current drug metabolism.

[49]  Peter Neuhaus,et al.  Sex is a major determinant of CYP3A4 expression in human liver , 2003, Hepatology.

[50]  P. Deuflhard,et al.  One-step and extrapolation methods for differential-algebraic systems , 1987 .

[51]  M E Andersen,et al.  Development of physiologically based pharmacokinetic and physiologically based pharmacodynamic models for applications in toxicology and risk assessment. , 1995, Toxicology letters.

[52]  Sean Ekins,et al.  Modeling of active transport systems. , 2002, Advanced drug delivery reviews.

[53]  J. Xu,et al.  DIFFERENTIAL INTERACTION OF 3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE INHIBITORS WITH ABCB1, ABCC2, AND OATP1B1 , 2005, Drug Metabolism and Disposition.

[54]  N. Ballatori,et al.  Identification of Glutathione as a Driving Force and Leukotriene C4 as a Substrate for oatp1, the Hepatic Sinusoidal Organic Solute Transporter* , 1998, The Journal of Biological Chemistry.

[55]  P. Neuvonen,et al.  Effect of itraconazole on the pharmacokinetics of atorvastatin , 1998, Clinical pharmacology and therapeutics.

[56]  Sean Ekins,et al.  A ligand-based approach to understanding selectivity of nuclear hormone receptors PXR, CAR, FXR, LXRalpha, and LXRbeta. , 2002, Pharmaceutical research.

[57]  D. Parke,et al.  Further evaluation of COMPACT, the molecular orbital approach for the prospective safety evaluation of chemicals. , 1998, Mutation research.

[58]  R. Kim,et al.  Polymorphisms in OATP-C , 2001, The Journal of Biological Chemistry.

[59]  Michael Gertz,et al.  Hepatocellular Binding of Drugs: Correction for Unbound Fraction in Hepatocyte Incubations Using Microsomal Binding or Drug Lipophilicity Data , 2008, Drug Metabolism and Disposition.

[60]  Bradley L Urquhart,et al.  Human Skeletal Muscle Drug Transporters Determine Local Exposure and Toxicity of Statins , 2010, Circulation research.

[61]  T. Sakaeda,et al.  Metabolic properties of the acid and lactone forms of HMG-CoA reductase inhibitors , 2004, Xenobiotica; the fate of foreign compounds in biological systems.

[62]  Tingjun Hou,et al.  ADME evaluation in drug discovery , 2002, Journal of molecular modeling.

[63]  P. Kollman,et al.  Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[64]  J. Shin,et al.  Contribution of cytochrome P450 3A4 and 3A5 to the metabolism of atorvastatin. , 2008, Xenobiotica; the fate of foreign compounds in biological systems.

[65]  A. Peyer,et al.  HMG‐CoA reductase inhibitors and P‐glycoprotein modulation , 2001, British journal of pharmacology.

[66]  Sean Ekins,et al.  Pharmacophore modeling of cytochromes P450. , 2002, Advanced drug delivery reviews.

[67]  Tingjun Hou,et al.  ADME Evaluation in Drug Discovery, 6. Can Oral Bioavailability in Humans Be Effectively Predicted by Simple Molecular Property-Based Rules? , 2007, J. Chem. Inf. Model..

[68]  Julia Qiu,et al.  Interactions of Human P-glycoprotein with Simvastatin, Simvastatin Acid, and Atorvastatin , 2004, Pharmaceutical Research.

[69]  C. Ioannides,et al.  An improved and updated version of the compact procedure for the evaluation of P450-mediated chemical activation. , 1998, Drug metabolism reviews.

[70]  Tingjun Hou,et al.  ADME Evaluation in Drug Discovery. 5. Correlation of Caco-2 Permeation with Simple Molecular Properties , 2004, J. Chem. Inf. Model..

[71]  Per Artursson,et al.  Expression of Thirty-six Drug Transporter Genes in Human Intestine, Liver, Kidney, and Organotypic Cell Lines , 2007, Drug Metabolism and Disposition.

[72]  J. Kramer,et al.  The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates , 2007, Nature Reviews Drug Discovery.

[73]  Wilhelm Huisinga,et al.  The virtual laboratory approach to pharmacokinetics: design principles and concepts. , 2006, Drug discovery today.

[74]  H. van de Waterbeemd,et al.  ADMET in silico modelling: towards prediction paradise? , 2003, Nature reviews. Drug discovery.

[75]  B. Ma,et al.  Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[76]  M Baker,et al.  Kinetic determinants of hepatic clearance: Plasma protein binding and hepatic uptake , 2007, Xenobiotica; the fate of foreign compounds in biological systems.

[77]  M Schwab,et al.  UDP‐Glucuronosyltransferase (UGT) Polymorphisms Affect Atorvastatin Lactonization In Vitro and In Vivo , 2010, Clinical pharmacology and therapeutics.

[78]  Jie Dai,et al.  Proteome, Phosphoproteome, and Hydroxyproteome of Liver Mitochondria in Diabetic Rats at Early Pathogenic Stages* , 2009, Molecular & Cellular Proteomics.

[79]  Andreas Zell,et al.  Main vector adaptation: a CMA variant with linear time and space complexity , 2001 .

[80]  D. Keppler,et al.  Vectorial transport by double-transfected cells expressing the human uptake transporter SLC21A8 and the apical export pump ABCC2. , 2001, Molecular pharmacology.

[81]  P. Stetson,et al.  Rabbit Serum Paraoxonase 3 (PON3) Is a High Density Lipoprotein-associated Lactonase and Protects Low Density Lipoprotein against Oxidation* , 2000, The Journal of Biological Chemistry.

[82]  N. Ballatori,et al.  Human organic anion transporter 1B1 and 1B3 function as bidirectional carriers and do not mediate GSH-bile acid cotransport. , 2007, American journal of physiology. Gastrointestinal and liver physiology.

[83]  N. Lameire,et al.  Pharmacokinetics of atorvastatin and its metabolites after single and multiple dosing in hypercholesterolaemic haemodialysis patients. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[84]  J H Lin,et al.  beta-Oxidation of simvastatin in mouse liver preparations. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[85]  Amin Rostami-Hodjegan,et al.  Simulation and prediction of in vivo drug metabolism in human populations from in vitro data , 2007, Nature Reviews Drug Discovery.

[86]  Kunal Roy,et al.  On Selection of Training and Test Sets for the Development of Predictive QSAR models , 2006 .

[87]  C. Daub,et al.  BMC Systems Biology , 2007 .

[88]  Johann Gasteiger,et al.  Analyzing Biochemical Pathways Using Neural Networks and Genetic Algorithms , 2006 .